P-selectin ligand protein
AssigneeGenetics Institute, Inc.
InventorsGlenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
Life of this patent
Estimating the term…
Abstract
A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.
Claims16
A method of reducing leukocyte adhesion to endothelial cells in a subject having an inflammatory disease comprising administering to the subject a therapeutically effective amount of a composition comprising a fusion protein comprising:
- (a) amino acid sequence comprising amino acid 42 to amino acid 60 of SEQ ID NO:2, and
- (b) the Fc portion of an antibody.
A method of reducing leukocyte adhesion to endothelial cells in a subject having a condition characterized by selectin-mediated intercellular adhesion by inhibiting selectin-mediated intercellular adhesion in the subject comprising administering to the subject a therapeutically effective amount of a fusion protein comprising:
- (a) an amino acid sequence comprising amino acid 42 to amino acid 60 of SEQ ID NO:2, and
- (b) the Fc portion of an antibody.
A method of reducing leukocyte adhesion to endothelial cells in a subject having a condition characterized by selectin-mediated intercellular adhesion, comprising administering a therapeutically effective amount of a soluble P-selectin ligand protein, or a fragment thereof having P-selectin ligand activity, wherein the soluble P-selectin ligand protein or fragment comprises amino acid 42 to amino acid 60 of SEQ ID NO:2.
A method of reducing leukocyte adhesion to endothelial cells in a subject having myocardial infarction comprising administering to the subject a therapeutically effective amount of a composition comprising a soluble P-selectin ligand protein comprising amino acid 42 to amino acid 88 of SEQ ID NO:2.
A method of reducing leukocyte adhesion to endothelial cells in a subject having a thrombotic disorder comprising administering to the subject a therapeutically effective amount of a composition comprising soluble P-selectin ligand protein comprising amino acid 42 to amino acid 88 of SEQ ID NO:2.
A method of reducing leukocyte adhesion to endothelial cells in a subject having a condition characterized by selectin-mediated intercellular adhesion comprising administering to the subject a therapeutically effective amount of a composition comprising a fusion protein comprising amino acid 42 to amino acid 313 of SEQ ID NO:
- 36.
Dependencies are inferred from the claim text.